Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 7374-7388

  Zhang, Wan ^a   Pelicano, Helene ^b   Yin, Ran ^a   Zeng, Junyi ^a   Wen, Tong ^a   Ding, Lu ^a   Huang, Ruibin ^a  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow stromal cell; Chronic lymphocytic leukemia; Combination strategy; Redox modulation; Suberoylanilide hydroxamic acid; phenylethyl isothiocyanate

Indexed keywords

CARDIOLIPIN; CASPASE 3; CYTOCHROME C; GLUTATHIONE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PHENETHYL ISOTHIOCYANATE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; ISOTHIOCYANIC ACID DERIVATIVE;

APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; OXIDATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REDOX STRESS; TUMOR MICROENVIRONMENT; UPREGULATION; ADULT; AGED; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; ISOTHIOCYANATES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 84943595859     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4364     Document Type: Article

References (47)

1. Keating, MJ, Chiorazzi, N, Messmer, B, Damle, RN, Allen, SL, Rai, KR, Ferrarini, M and Kipps, TJ: Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003, 153-175, 2003.
2. Tam CS and Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20: 479-498, 2007.
3. Chiorazzi N, Rai KR and Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 352: 804-815, 2005.
4. Munk Pedersen I and Reed J: Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 45: 2365-2372, 2004.
5. Silber R, Farber CM, Papadopoulos E, Nevrla D, Liebes L, Bruck M, Brown R and Canellakis ZN: Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 80: 2038-2043, 1992.
6. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH and Kerr JF: Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 71: 343-350, 1989.
7. Zhou Y, Hileman EO, Plunkett W, Keating MJ and Huang P: Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 4098-4104, 2003.
8. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ and Huang P: Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 14, 276-286, 2012.
9. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
10. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
11. Rosato RR, Almenara JA and Grant S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637-3645, 2003.
12. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, et al: Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound-phenylethyl isothiocyanate. Blood 116: 2732-2741, 2010
13. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166-173, 2006.
14. Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D and Lagneaux L: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 95, 1136-1143, 2010.
15. Perez-Perarnau A, Coll-Mulet L, Rubio-Patino C, Iglesias-Serret D, Cosialls AM, Gonzalez-Girones DM, de Frias M, de Sevilla AF, de la Banda E, Pons G and Gil J: Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 6: 1228-1235, 2011.
16. Abou-Nassar, K. & Brown, J-R. Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol 8, 886-895.
17. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, et al: Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147: 507-514, 2009.
18. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, et al: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005.
19. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S and Rai KR: National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996.
20. Huang P, Sandoval A, Van Den Neste E, Keating MJ and Plunkett W: Inhibition of RNA transcription: A biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14: 1405-1413, 2000.
21. Iverson SL and Orrenius S: The cardiolipin-cytochrome c interaction and the mitochondrial regulation of apoptosis. Arch Biochem Biophys 423: 37-46, 2004.
22. Zenkov NK, Menshchikova EB and Tkachev VO: Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc) 78: 19-36, 2013.
23. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, et al: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112: 1912-1922, 2008.
24. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, et al: Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175: 913-923, 2006.
25. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005.
26. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD and Yamamoto M: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
27. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M and Talalay P: Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99: 11908-11913, 2002.
28. Lu SC: Regulation of glutathione synthesis. Curr Top Cell Regul 36: 95-116, 2000.
29. Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454, 2002.
30. Balakrishnan K, Burger JA, Wierda WG and Gandhi V: AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113: 149-153, 2009.
31. Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, et al: Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction and miR34a in a prospective clinical trial. Blood 114: 2589-2597, 2009.
32. Caligaris-Cappio F: Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol 4: 5-21, 2000.
33. Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035, 2004.
34. Okabe S, Tauchi T, Kimura S, Maekawa T, Kitahara T, Tanaka Y and Ohyashiki K: Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: A potential treatment for BCR-ABL-positive leukemia. PLoS One 9: e89080, 2014.
35. Thurn KT., Thomas S, Moore A and Munster PN: Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7, 263-283, 2011.
36. Nimmanapalli R, Fuino L, Stobaugh C, Richon V and Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236-3239, 2003.
37. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM and Pandolfi PP: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330, 2001.
38. VanderMolen KM, McCulloch W, Pearce CJ and Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 64: 525-531, 2011.
39. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066, 2008.
40. Kansanen E, Kuosmanen SM, Leinonen H and Levonen AL: The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol 1, 45-49, 2013.
41. Bannai S: Transport of cystine and cysteine in mammalian cells. Biochim Biophys Acta 779: 289-306, 1984.
42. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et al: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 91: 3379-3389, 1998.
43. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F and Wang X: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486, 2003.
44. Adams KW and Cooper GM: Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 282: 6192-6200, 2007.
45. Inoue S, Walewska R, Dyer MJ and Cohen GM: Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 22: 819-825, 2008.
46. Ghezzi P: Regulation of protein function by glutathionylation. Free Radic Res 39: 573-580, 2005.
47. An X, Schulz VP, Li J, Wu K, Liu J, Xue F, Hu J, Mohandas N and Gallagher PG: Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood 123: 3466-3477, 2014.